JPRN-UMIN000003533已完成2 期
A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy - A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy
Hanshin Cancer Study Group0 个研究点目标入组 90 人开始时间: 2010年4月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)history of drug induced interstitial pneumonia 3)history of severe drug allergy 4)patients previously treated with S-1 and docetaxel. 5)history of active infection or other serious disease condition 6)history of poorly controlled pleural effusion,pericardial effusion and ascites 7)history of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,heart failure, etc.) 8)uncontrollable hypertension 9)uncontrollable diabetes mellitus 10)curative radiotherapy pretreated to the chest. 11)current history of hemosputum 12)current or previous history hemoptysis 13)current or previous (within the last 1 year) history of cerebrovascular disease 14)current or previous (within the last 1 year) history of GI perforation 15)symptomatic brain metastasis 16)traumatic fracture of unrecovery 17)the operation has been scheduled for the examination period 18)tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor 19)evidence of bleeding diathesis or coagulopathy 20)thrombosis that need to treat 21)severe drug allergy for 80 polysorbate content medicine 22)patients using Flucytosine 23)patients with contraindication of medication (DTX,S-1). 24)history of active double cancer 25)history of active psychological disease 26)history of pregnancy or lactation 27)any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
研究者
相似试验
已完成
2 期
A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 as second line therapy in wild-type EGFR Patients with Non-Squamous Non-Small-Cell Lung Cancer. After failure to first line therapy, platinum doublet plus bevacizumab.on-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000009602ung Oncology Group in Kyushu, Japan (LOGIK)60
已完成
2 期
A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer.Stage IVB, recurrent or persistant cervical cancerJPRN-UMIN000026063Japan Gynecologic Oncology Group:JGOG70
已完成
2 期
A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIson-squamous Non-small-cell Lung CancerJPRN-UMIN000003263Hanshin Cancer Study Group30
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45